


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of claims:

1. (Currently Amended) A method for treating cancer treatable by the inhibition of more than one protein kinase, comprising ~~modulating~~ inhibiting the activity of more than one protein kinase, comprising administering to a patient ~~in need thereof~~ having a cancer treatable by the inhibition of more than one protein kinase an effective amount of the compound of having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>,  
-(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>(CH<sub>2</sub>)<sub>c</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>,  
-(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)NR<sub>6</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>OR<sub>5</sub>,  
-(CH<sub>2</sub>)<sub>b</sub>SO<sub>d</sub>R<sub>5</sub> or -(CH<sub>2</sub>)<sub>b</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -OC(=O)R<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

2. (Canceled)

3. (Original) The method of claim 1 wherein R<sub>1</sub> is aryl optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

4. (Withdrawn) The method of claim 1 wherein R<sub>1</sub> is heteroaryl optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

5. (Original) The method of claim 1 wherein R<sub>4</sub> is substituted heterocycle.

6. (Withdrawn) The method of claim 1 wherein R<sub>4</sub> is 3-triazolyl, optionally substituted at its 5-position with:

(a) a C<sub>1</sub>-C<sub>4</sub> straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or

(b) a 2-pyrrolidinyl group.

7. (Original) The method of claim 1, wherein -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3.

8. (Original) The method of claim 1, wherein the protein kinase is a protein tyrosine kinase.

9. (Canceled)

10. (Currently Amended) The method of claim 9 1, wherein the activities of the protein kinases are simultaneously inhibited.

11. (Original) The method of claim 1, wherein the protein kinase is Aurora-A, AKT, CDK1/cyclinB(h), CDK2/cyclinA(h), CDK3/cyclinE(h), CDK5/p35(h), CDK6/cyclinD3(h), CDK7/cyclinH/MAT1, CHK1, CHK2, EGFR, c-RAF, RAS, cSRC, Yes, Fyn, Lck, Fes, Lyn, Syk, Bmx, FGFR3, GSK3 $\alpha$ , GSK3 $\beta$ , PI3, IGF-1R, MAPK2, MAPKAP-K2, JNK, MEK1,

p70S6K, PAK2, PDGFR $\alpha$ , PDGFR $\beta$ , PDK1, PKA, PKC $\epsilon$ , PKC $\mu$ , PKD2, VEGF, PRAK, PRK2, ROCK-II, Rsk1, Rsk2, Rsk3 or SGK.

12. (Original) The method of claim 8, wherein the activities of the protein tyrosine kinases are selectively inhibited over non-tyrosine kinases.

13. (Currently Amended) The method of claim 1, wherein the activities of Auroa-A, Blk, CDK1, CDK2, CDK3, CDK5, CDK6, CHK1, CHK2, Src family of kinases, cSrc, Yes, Fyn, Lck, Fes, , Lyn, Syk, , FGF-R3, GSK3a, GSK3b, MAPK family including JNK, MEK, p70S6K, PKCmu, PKD2, PRAK, PRK2, ROCK-II, RSK1, RSK2 and RSK3 are selectively ~~modulated~~ inhibited over other kinases.

14-16. (Canceled)

17. (Currently Amended) The method of claim ~~16~~ 1, wherein the cancer is of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system

18. (Withdrawn) The method of claim 1, wherein the disease is an inflammatory disease.

19. (Withdrawn) The method of claim 18, wherein the inflammatory disease is hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, Type I diabetes, diabetes insipidus, diabetes mellitus, maturity-onset diabetes, juvenile diabetes, insulin-dependant diabetes, non-insulin dependant diabetes, malnutrition-related diabetes, ketosis-prone diabetes, ketosis-resistant diabetes, hearing loss, otitis externa, acute otitis media, chronic obstructive pulmonary disease, pulmonary interstitial fibrosis, acute respiratory distress syndrome, renal fibrosis, liver fibrosis, cystic fibrosis, wound-healing, burn-healing, allergy, allergic rhinitis, acute respiratory distress syndrome, systemic lupus erythematosus, nephropathy, pancreatitis, peritonitis or ischemia-reperfusion injury.

20. (Withdrawn) The method of claim 1, wherein the disease is a liver disease.

21. (Withdrawn) The method of claim 20, wherein the liver disease is hepatitis, alcohol-induced liver disease, toxin-induced liver disease, steatosis or sclerosis.

22. (Withdrawn) The method of claim 1, wherein the disease is a cardiovascular disease.

23. (Withdrawn) The method of claim 22, wherein the cardiovascular disease is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, myocardial infarction, chronic obstructive pulmonary disease or stroke.

24. (Withdrawn) The method of claim 1, wherein the disease is a neurodegenerative disease.

25. (Withdrawn) The method of claim 24, wherein the neurodegenerative disease is epilepsy, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, peripheral neuropathies, spinal cord damage, AIDS dementia complex or Parkinson's disease.